Evotec SE (NASDAQ:EVO – Get Free Report)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $3.30, but opened at $3.39. Evotec shares last traded at $3.40, with a volume of 17,661 shares.
Evotec Stock Performance
The firm’s 50 day moving average price is $3.78 and its 200-day moving average price is $4.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in EVO. Wellington Management Group LLP lifted its position in shares of Evotec by 29.7% in the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock worth $9,616,000 after acquiring an additional 602,858 shares during the period. DCF Advisers LLC raised its stake in shares of Evotec by 5.9% in the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock valued at $956,000 after purchasing an additional 12,816 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Evotec in the fourth quarter worth $27,000. Bank of America Corp DE boosted its stake in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares in the last quarter. Finally, Lighthouse Investment Partners LLC bought a new stake in Evotec in the 4th quarter valued at $166,000. Institutional investors own 5.81% of the company’s stock.
Evotec Company Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.
Recommended Stories
- Five stocks we like better than Evotec
- How Can Investors Benefit From After-Hours Trading
- Congress! Who Traded What During the Tariff-Induced Meltdown
- 3 Tickers Leading a Meme Stock Revival
- 2 Under-the-Radar Consumer Staples Stocks With Big Dividends
- Manufacturing Stocks Investing
- NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
